{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:04Z","timestamp":1786987024861,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clgc.2013.04.029","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T16:45:48Z","timestamp":1373042748000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Joshua M.","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan T.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Buehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Staab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Malkovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"McNeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2013.04.029_bib1","first-page":"212","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2013.04.029_bib2","first-page":"S42","article-title":"Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era","volume":"170","author":"D'Amico","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib3","first-page":"910","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib4","first-page":"450","article-title":"Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival","volume":"156","author":"Lee","year":"1996","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.04.029_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ucl.2005.12.008","article-title":"Managing complications of androgen deprivation therapy for prostate cancer","volume":"33","author":"Holzbeierlein","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2013.04.029_bib7","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.04.029_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clgc.2013.04.029_bib9","first-page":"1219","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2013.04.029_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2008.08156.x","article-title":"Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer","volume":"103","author":"Panju","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2013.04.029_bib12","first-page":"181","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1078155211402105","article-title":"Bone health management in prostate cancer patients receiving androgen deprivation therapy","volume":"18","author":"Dhanapal","year":"2012","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clgc.2013.04.029_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/JBMR.040813","article-title":"Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer","volume":"19","author":"Morabito","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clgc.2013.04.029_bib15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2013.04.029_bib16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2013.04.029_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2013.04.029_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2013.04.029_bib19","first-page":"2008","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib20","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.04.029_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.04.029_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N","article-title":"Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment","volume":"249","author":"Pataki","year":"1997","journal-title":"Anat Rec"},{"key":"10.1016\/j.clgc.2013.04.029_bib23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00256-011-1164-9","article-title":"Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies","volume":"40","author":"Reid","year":"2011","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.clgc.2013.04.029_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature","volume":"38","author":"Gnant","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2013.04.029_bib25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.171.5.1567","article-title":"Gamma\/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis","volume":"171","author":"Fisch","year":"1990","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clgc.2013.04.029_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2013.04.029_bib27","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0264-410X(02)00070-1","article-title":"Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?","volume":"20","author":"Gougeon","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.clgc.2013.04.029_bib28","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/eji.1830181218","article-title":"Structural and serological heterogeneity of gamma\/delta T cell antigen receptor expression in thymus and peripheral blood","volume":"18","author":"Lanier","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clgc.2013.04.029_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0684.1992.tb00576.x","article-title":"Are gamma delta T cells important for the elimination of virus-infected cells?","volume":"21","author":"Malkovsky","year":"1992","journal-title":"J\u00a0Med Primatol"},{"key":"10.1016\/j.clgc.2013.04.029_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002620100173","article-title":"Gamma\/delta T cells provide innate immunity against renal cell carcinoma","volume":"50","author":"Kobayashi","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2013.04.029_bib31","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in\u00a0vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2013.04.029_bib32","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.04.029_bib33","first-page":"337","article-title":"Castration alters peripheral immune function in normal male mice","volume":"84","author":"Viselli","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.clgc.2013.04.029_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.humimm.2010.02.007","article-title":"Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses","volume":"71","author":"Morse","year":"2010","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clgc.2013.04.029_bib35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pros.22476","article-title":"T\u00a0cells localized to the androgen-deprived prostate are T(H) 1 and T(H) 17 biased","volume":"72","author":"Morse","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2013.04.029_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.imlet.2004.06.009","article-title":"Immune-based therapies for prostate cancer","volume":"96","author":"McNeel","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.clgc.2013.04.029_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocd.2007.12.007","article-title":"Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference","volume":"11","author":"Baim","year":"2008","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.clgc.2013.04.029_bib38","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clgc.2013.04.029_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2013.04.029_bib40","first-page":"972","article-title":"Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer","volume":"176","author":"Ryan","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2013.04.029_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clgc.2013.04.029_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2009.11.083","article-title":"The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis","volume":"75","author":"Campbell","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2013.04.029_bib43","unstructured":"Zometa\/Reclast (Zoledronic Acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals;\u00a02001."},{"key":"10.1016\/j.clgc.2013.04.029_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clinthera.2008.03.008","article-title":"Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment","volume":"30","author":"Sebba","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clgc.2013.04.029_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J\u00a0Clin Densitom"},{"key":"10.1016\/j.clgc.2013.04.029_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00223-010-9403-y","article-title":"Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate","volume":"87","author":"Miller","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clgc.2013.04.029_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrendo.2009.246","article-title":"Bone: bone density screening leads to reduced fracture risk","volume":"6","author":"Watts","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clgc.2013.04.029_bib48","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.04.029_bib49","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.04.029_bib50","first-page":"97","article-title":"Biochemical markers of bone turnover: part I: biochemistry and variability","volume":"26","author":"Seibel","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.clgc.2013.04.029_bib51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/ncponc0320","article-title":"Clinical use of markers of bone turnover in metastatic bone disease","volume":"2","author":"Seibel","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.clgc.2013.04.029_bib52","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313000906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313000906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:24:22Z","timestamp":1761564262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767313000906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1558767313000906"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.04.029","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}